PharmStars Announces “Innovations in Real-World Evidence” Theme for Fall 2022 Accelerator

PharmStars Announces “Innovations in Real-World Evidence” Theme for Fall 2022 Accelerator

PharmStars, the pharma-focused accelerator for digital health startups, announces it is now accepting applications for its Fall 2022 cohort with the theme, “Innovations in Real-World Evidence.” - June 15, 2022 - PharmStars

Defined Bioscience Announces Formation of Scientific Advisory Board

Defined Bioscience, a life science tools company pioneering the development of next generation ingredients for cell culture, today announced the formation of its scientific advisory board (SAB). The SAB is comprised of a distinguished group of academic and industry experts who will advise the... - June 15, 2022 - Defined Bioscience Inc.

Creative Diagnostics Introduces CC50/IC50 Assay Services for Pharmaceutical Safety

Creative Diagnostics introduced CC50/IC50 testing services with a high level of detection sensitivity and accuracy. - June 11, 2022 - Creative Diagnostics

Creative Diagnostics Launches Measles Virus Antigens for the Detection of Antibodies

Creative Diagnostics announced the release of new measles virus antigens suitable for both IgM and IgG detection. - June 11, 2022 - Creative Diagnostics

PharmStars Announces Showcase Pitch Event for Spring 2022 Cohort

PharmStars Announces Showcase Pitch Event for Spring 2022 Cohort

PharmStars, the pharma-focused accelerator for digital health startups, announces the start of its Showcase Event on June 8, 2022. The digital health startups that participated in the 10-week accelerator program will make formal presentations to, and answer questions from, the pharma members of PharmStars. All of PharmStars’ seven members are participating in the Showcase Event. - June 08, 2022 - PharmStars

Eledon Announces Phase 2a Trial Results of Tegoprubart (AT-1501) – a Drug Invented at ALS TDI

Eledon Announces Phase 2a Trial Results of Tegoprubart (AT-1501) – a Drug Invented at ALS TDI

Eledon Pharmaceuticals announced topline results from their Phase 2 trial of tegoprubart (formerly AT1501), a drug invented and developed at the ALS Therapy Development Institute (ALS TDI). The Phase 2a trial in ALS was a 12-week, open label, dose escalating, safety, and biomarker study. The... - May 31, 2022 - ALS Therapy Development Institute

Scientific Reports Publishes Data Demonstrating VR Platform Produces Peak Experiences, Ego Attenuation & Connectedness Comparable to Moderate Dose Psychedelics

Scientific Reports Publishes Data Demonstrating VR Platform Produces Peak Experiences, Ego Attenuation & Connectedness Comparable to Moderate Dose Psychedelics

aNUma, Inc., a digital therapeutics company building virtual reality programs to address the global mental health crisis, today, announced that Scientific Reports has published research demonstrating technology like that behind aNUma’s VR platform can deliver peak experiences, ego attenuation, and connectedness comparable to psychedelics. This study, written by Dr. David Glowacki and colleagues, is the first of its kind to be published in a leading peer-reviewed journal. - May 30, 2022 - aNUma

Creative Diagnostics Announces Antigens for Epstein-Barr Virus Antibody Tests

Creative Diagnostics recently launched recombinant antigens p18 and p23 (viral capsid antigens, VCA), p54 and p138 (early antigens, EA) and EBNA1 (nuclear antigen, EBNA). - May 26, 2022 - Creative Diagnostics

Creative Diagnostics Launches Antibody-Dependent Enhancement Assay Services

Creative Diagnostics recently introduces comprehensive services for antibody-dependent enhancement (ADE) assay. - May 26, 2022 - Creative Diagnostics

ALS Therapy Development Institute Scientists to Present Posters Sharing Research Advancements at the ALS Drug Development Summit

ALS Therapy Development Institute Scientists to Present Posters Sharing Research Advancements at the ALS Drug Development Summit

The ALS TDI scientists will be showcasing significant advancements in ALS research through multiple poster presentations. These posters will cover pre-clinical research exploring potential new therapeutic drug-like molecules and targets for ALS, as well as translational research analyzing patient data to identify new ALS biomarkers, drug targets, and patient populations. - May 25, 2022 - ALS Therapy Development Institute

Molekule Consulting Announces the Launch of E.U. - Based Operations

Molekule Consulting Announces the Launch of E.U. - Based Operations

Molekule Consulting announces the launch of an E.U. - based business / Molekule Hub continuing their focus on the development of global strategy and advisory services for the biopharmaceutical sector. - May 24, 2022 - Molekule Consulting

Biopharma Industry Standout Robert Proulx Joins Advisory Board of Global Cancer Technology

Biopharma Industry Standout Robert Proulx Joins Advisory Board of Global Cancer Technology

Global Cancer Technology is developing innovative treatments for deadly diseases like cancer, with a current focus on glioblastoma and breast cancer. To date, Mr. Robert Proulx has held numerous Board positions, is a recognized thought leader in biopharma, and currently holds dual roles as the founder and CEO of Imagion Biosystems. - May 21, 2022 - Global Cancer Technology

NuvOx Pharma Announces Issuance of a New Patent

NuvOx Pharma has been issued US Patent No. 11,304,899, entitled “Compositions of fluorocarbon nanoemulsion, and methods of preparation and use thereof.” - May 19, 2022 - NuvOx Pharma

NuvOx Appoints Dr. Robert King to SAB

NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, appointed Dr. Robert King to its Scientific Advisory Board (SAB). Dr. King is a seasoned life science executive with over 30 years’... - May 11, 2022 - NuvOx Pharma

The ALS TDI Discovery Biology Suite Dedicated in Honor of Liz Bodine to Speed Drug Development in ALS

The ALS TDI Discovery Biology Suite Dedicated in Honor of Liz Bodine to Speed Drug Development in ALS

The ALS Therapy Development Institute (ALS TDI) and Augie’s Quest to Cure ALS are proud to honor the commitment of Liz Bodine to facilitate more effective ALS drug discovery at ALS TDI, the world’s most comprehensive drug discovery lab dedicated solely to ALS. - May 04, 2022 - ALS Therapy Development Institute

Cyclists Support ALS Research with 3-Day, 270-Mile Ride from Boston to Greenwich in Tri-State Trek

Cyclists Support ALS Research with 3-Day, 270-Mile Ride from Boston to Greenwich in Tri-State Trek

Hundreds of riders to join the ride to end ALS this June and raise funds for cutting-edge ALS research. ALS TDI has received a $100,000 match for all donations made to the Tri-State Trek through the month of May. - May 03, 2022 - ALS Therapy Development Institute

Creative Diagnostics Introduces New Nipah Virus Antigens and Antibodies

Creative Diagnostics recently launches a series of NiV recombinant antigen and antibody pairs. - April 30, 2022 - Creative Diagnostics

“Fight ALS Film Fest” Aims to Shine a Spotlight on the World of ALS

Films explore universal themes of life-changing diseases through examination of ALS. Films and dialogue aim to improve understanding, uplift those affected, and expand the community. - April 25, 2022 - ALS Therapy Development Institute

American Laboratory Products Company Merges with GeneProof

American Laboratory Products Company, Ltd. (“ALPCO”), a specialty in vitro diagnostics company, today announced a merger with GeneProof a.s. (“GeneProof”), a leading molecular diagnostics company based in Brno, Czech Republic. The combination creates a global market leader... - April 21, 2022 - ALPCO

Microvascular Therapeutics Finalizes Facility Certification for the Production of Its Product, MVT-100

Microvascular Therapeutics (MVT), a clinical stage biotechnology company, finalized its manufacturing facility certifications for the GMP production of its first product, MVT-100. - April 21, 2022 - Microvascular Therapeutics

NuvOx Technology Featured in Prominent Peer Review Journal

NuvOx Pharma’s technology, which is developed as a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, was featured in the prominent journal of Frontiers of Neurology. - April 19, 2022 - NuvOx Pharma

NuvOx Finalizes Facility Certification, Poising for Phase IIb Trials

NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, finalized its manufacturing facility certifications for Phase IIb trials. - April 17, 2022 - NuvOx Pharma

Dr. Claudia C. Cotca of C3 Think Tank Appointed as Advisor Chair of Advanced Technology Academic Research Center (ATARC) on Digital AI & Data Analytics Warfighter Health

Dr. Claudia C. Cotca of C3 Think Tank appointed as Advisor Chair of Advanced Technology Academic Research Center (ATARC) on Digital AI & Data Analytics Warfighter Health. Together with leadership and military health experts, stakeholders and program officers, Dr. Claudia C Cotca will help support and contribute to the scope and mission of ATARC’s Warfighter Health in incorporating responsibly artificial intelligence in military medicine. - April 13, 2022 - C3 Think Tank

Biolexis Therapeutics Announces Poster Presentation at AACR 2022 Annual Meeting

Biolexis Therapeutics Inc., a leader in bio-tech research and creator of the FIELDS™ process, today announced that data highlighting an orally available, CDK9 selective small molecule inhibitor showing promise in n-Myc-driven neuroendocrine prostate cancers (NEPC) was presented in a poster at... - April 11, 2022 - Biolexis Therapeutics Inc.

Microvascular Therapeutics Receives Funds from Commercialization Readiness Program for the Development of Its Ultrasound Contrast Agent, MVT-100

MicrovMicrovascular Therapeutics (MVT), a biotechnology company based in Tucson, AZ, was recently awarded a Commercialization Readiness Program grant from the National Institute of Heart, Lung, and Blood Institute (NHLBI). Wyatt Unger, MD, MBA, Chief Medical Officer of MVT said, “We are... - April 09, 2022 - Microvascular Therapeutics

Instant Systems Expands Its Footprint in Virginia

Instant Systems Expands Its Footprint in Virginia

Instant Systems continues to expand their footprint in Southeast Virginia with the launch of their Central Supply and Order Fulfilment Center (N3) in Virginia Beach, VA. Increased demand for Instant Systems’ products and services is driving the need for more warehouse, production and R&D... - April 07, 2022 - Instant Systems

Creative Diagnostics Launches Staphylococcal Enterotoxin Antigens

Creative Diagnostics recently launches a range of natural and recombinant staphylococcal enterotoxin antigens. - March 31, 2022 - Creative Diagnostics

New Product for Solar Cells from Solaris Chem (Canada)

Solaris Chem expands its product offering for solar cell applications. - March 19, 2022 - Solaris Chem Inc.

Solaris Chem Products Are Now Available in Germany Through Hözel

Their distribution partner in Germany, Hözel, has included Solaris Chem's products to its range for the biotechnology sector. Hözel has been a well-established company since its foundation in 1993. Thanks to its long-standing market presence, it has a lot of experience and knowledge in... - March 19, 2022 - Solaris Chem Inc.

ALPCO Announced Its Support of the Ukrainian People in a Company-Wide Communication to Its Employees

ALPCO (Salem, NH) announced its support of the Ukrainian people in a company-wide communication to its employees. The message outlined the company's contribution to aid refugees through the American Red Cross and Project Hope in the amount of $5,000 each. Additionally, ALPCO is offering an... - March 16, 2022 - ALPCO

NuvOx Receives Notice from the Breakthrough DOD Award for Its Immuno-Oncology Program

On February 11th, 2022, NuvOx Pharma received notice from the Department of Defense (DOD) office of the Congressionally Directed Medical Research Programs (CDMRP) that the Company has been awarded a grant from the Breast Cancer Research Program Breakthrough Award. The grant would fund a... - March 05, 2022 - NuvOx Pharma

Thrivous Introduces Personalized Medicine Coaching

Thrivous, the human enhancement company, has partnered with Consolidated Health Solutions to provide personalized medicine coaching. Thrivous' mission is to help customers access technology with the greatest potential to improve their brains and bodies. Customers may achieve better results when... - March 03, 2022 - Thrivous

Locus Fermentation Solutions Selected for Evolution of Manufacturing Award by Smart Business Magazine

Northeast Ohio startup recognized for its innovative biological manufacturing with a near-zero carbon footprint. - February 27, 2022 - Locus Fermentation Solutions

FOXG1 Research Foundation Hosts Napa Valley Charity Golf Tournament to Accelerate Research for Pediatric Neurological Disorder

FOXG1 Research Foundation Hosts Napa Valley Charity Golf Tournament to Accelerate Research for Pediatric Neurological Disorder

Scientists believe FOXG1 may hold the key to unlocking brain disorders affecting millions, including autism, Alzheimer’s, brain tumors and more. - February 23, 2022 - FOXG1 Research Foundation

Timothy Healey Joins the Board of Director at Microvascular Therapeutics

Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Timothy Healey to the MVT Board of Directors. Mr. Healey bring a global perspective to pharmaceutical launch and commercialization. “I am very pleased and honored... - February 23, 2022 - Microvascular Therapeutics

NuvOx to Participate in the BIO CEO Investor Conference

NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, will participate in BIO CEO & Investor Conference, held at New York City from February 14 - 17, 2022. The management team will be... - February 11, 2022 - NuvOx Pharma

FOXG1 Research Foundation’s Hourinaz Behesti PhD to Present at BIO CEO & Investor Conference 2022

FOXG1 Research Foundation’s Hourinaz Behesti PhD to Present at BIO CEO & Investor Conference 2022

The FOXG1 Research Foundation, the rare disease patient organization that is driving the science to find treatments for FOXG1 syndrome, will be presenting at the BIO CEO & Conference on February 14 to discuss Tapping into Therapeutic Development for Rare CNS Disorders. Dir. of Science, Hourinaz Behesti will discuss why FOXG1 is a viable target for biotech investment, and the suite of assets that the FRF has developed and characterized to help accelerate drug development. - February 09, 2022 - FOXG1 Research Foundation

ImaRx Investments Receives ISO-7 Certification for Its GMP Manufacturing Suite: Both Microvascular Therapeutics and NuvOx Pharma Will Benefit

ImaRx Investments, LLC, an investment firm based in Tucson, Arizona, has received ISO-7 certification on February 1st for its GMP manufacturing suite. The 1,800 square foot, ISO-5 capable clean room is designed for manufacturing injectable drugs. The facility is the only one of its kind in Southern... - February 08, 2022 - Microvascular Therapeutics

Bioplastics International Launches Water Soluble PVA Replacement for Plastics

Bioplastics International creates water soluble PVA products to replace plastics, to stop the plastic pollution of our oceans and beaches. - February 07, 2022 - Bioplastics International

Shiv Kapoor Joins the Board of Directors at Microvascular Therapeutics

Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Shiv Kapoor to the MVT Board of Directors. Mr. Kapoor will bring extensive experience in corporate strategy and financing from both biotechnology and finance... - February 03, 2022 - Microvascular Therapeutics

MacroArray Diagnostics GmbH (MADx) Partners with ALPCO to Offer a Fully Automated Sample-to-Answer Multiplex Allergy Test Solution to the North American Market

ALPCO (Salem, NH), a leading US producer of novel immunoassay testing platforms, recently announced an exclusive distribution partnership with MacroArray Diagnostics GmbH (Vienna, Austria). Together, they offer a comprehensive line of testing solutions for allergies (IgE-based) and food intolerances (IgG-based), from test material to proprietary hardware and software to process and analyze samples. - February 01, 2022 - ALPCO

Jubilance, Clinically-Proven PMS Relief Supplement, Gets Makeover for 2022

Women's Wellness company Jubilance offers suite of free wellness resources to help women feel their best all month long. Resources include therapist-designed guided meditations for specific PMS symptoms, a PMS research library, curated women's health guides, podcasts, playlists and more. Clinically proven PMS relief supplement Jubilance announces new label makeover for 2022 to better reflect that jubilant feeling of freedom from PMS anxiety, gloominess, stress and irritability. - January 26, 2022 - Jubilance for PMS

NuvOx to Present at Various Bio Forums in JPM Week

NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, will participate in various Bio forums held Jan 10 – 14, 2022. Dr. Evan Unger, NuvOx’s Chief Executive Officer, is presenting in... - January 14, 2022 - NuvOx Pharma

PharmStars Now Accepting Applications for Spring 2022 Accelerator Program; Startups with Digital Innovations in Neurological Disease Are Welcome to Apply

PharmStars Now Accepting Applications for Spring 2022 Accelerator Program; Startups with Digital Innovations in Neurological Disease Are Welcome to Apply

PharmStars, the pharma-focused accelerator for digital health startups, is now accepting applications for its spring 2022 cohort with the theme, “Digital Innovations in Neurological Disease.” - January 04, 2022 - PharmStars

Mirror Biologics Announces Appointment of Dr. David Fineberg as Chief Medical Officer

Mirror Biologics Announces Appointment of Dr. David Fineberg as Chief Medical Officer

Mirror Biologics, Inc., a clinical stage immunotherapy company specializing in the development, manufacturing, commercialization and clinical translation of next generation immunomodulatory and therapeutic in-situ vaccines for cancer and infectious diseases, today announced the appointment of David... - December 26, 2021 - Mirror Biologics, Inc.

Global Regenerative Academy Announces Prof. Tahsin Beyzadeoglu as President

Global Regenerative Academy Announces Prof. Tahsin Beyzadeoglu as President

Global Regenerative Academy, independent subsidiary of the Global Regenerative Group Inc., has new board leadership. GRA President is now Prof. Tahsin Beyzadeoglu as announced during the opening Ceremony of GRC Dubai 2021 (November 19-21, 2021) by Mr. Mihail Blagoev (GRG Inc. VP) after being elected by the Scientific Board. - December 21, 2021 - Global Regenerative Academy

Mirror Biologics, Inc. Announces Close of a $14 Million Financing Round

Mirror Biologics, Inc. Announces Close of a $14 Million Financing Round

This Funding will be Used, in Part, to Launch an Asian Phase II/III Randomized Controlled Registration Trial for Advanced Liver Cancer in Q1/2-2022. - December 09, 2021 - Mirror Biologics, Inc.

PharmStars Announces 2021 Accelerator Graduates

PharmStars Announces 2021 Accelerator Graduates

12 digital health startups have successfully completed PharmStars’ inaugural 10-week pharma-focused accelerator program. - December 08, 2021 - PharmStars

Doubling Down: HCPA Panel Selects Locus Performance Ingredients for Two Innovation Awards at XPAND2021

Doubling Down: HCPA Panel Selects Locus Performance Ingredients for Two Innovation Awards at XPAND2021

Green Tech Start-Up Recognized for Advancing Sustainable Cleaning Products with High-Performance Biosurfactant Ingredients and Carbon-Neutral Production Process. - December 08, 2021 - Locus Performance Ingredients

Pelvic Floor HIFEM (Emsella) Improves the Intensity and Duration of Male Orgasm

Dr. Judson Brandeis studied the Emsella, a device that has been FDA-approved for the treatment of urinary incontinence by stimulating the pelvic floor muscles, in mid-life men with weak or delayed ejaculation. He discovered that four weekly thirty-minute treatments with the Emsella protocol 2 was enough to improve the self-reported intensity and duration of ejaculation. - November 30, 2021 - BrandeisMD

Press Releases 1 - 50 of 3,042